James Toouli Selected Research

galantide (M 15)

8/2010	Octreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice.
6/2010	The efficacy of combining feG and galantide in mild caerulein-induced acute pancreatitis in mice.
3/2010	Galanin mediates the pathogenesis of cerulein-induced acute pancreatitis in the mouse.
2/2010	The combination of neurokinin-1 and galanin receptor antagonists ameliorates caerulein-induced acute pancreatitis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James Toouli Research Topics

Disease

8	Pancreatitis 01/2012 - 01/2005
5	Weight Loss (Weight Reduction) 01/2019 - 03/2003
5	Pain (Aches) 05/2016 - 08/2002
4	Obesity 01/2019 - 09/2014
3	Sphincter of Oddi Dysfunction 10/2020 - 04/2002
3	Morbid Obesity 09/2014 - 03/2003
2	Type 2 Diabetes Mellitus (MODY) 05/2016 - 05/2016
2	Heartburn (Pyrosis) 05/2016 - 09/2014
2	Necrosis 03/2010 - 02/2010
2	Obstructive Jaundice (Cholestatic Jaundice) 01/2006 - 09/2002
1	Constipation 05/2016
1	Dyspepsia (Indigestion) 09/2014
1	Abdominal Pain (Pain, Abdominal) 09/2014
1	Body Weight (Weight, Body) 09/2014
1	Fibrosis (Cirrhosis) 07/2012
1	Insulin Resistance 07/2012
1	Non-alcoholic Fatty Liver Disease 07/2012
1	Neurogenic Inflammation 06/2010
1	Neoplasms (Cancer) 03/2010
1	Hyperamylasemia 02/2010
1	Hernia (Hernias) 01/2005
1	Inguinal Hernia (Direct Inguinal Hernia) 01/2005
1	Acute Cholecystitis 10/2003
1	Gallstones (Gallstone) 03/2003
1	Shock 09/2002
1	Sepsis (Septicemia) 09/2002

Drug/Important Bio-Agent (IBA)

6	CeruletideIBA 01/2012 - 04/2008
4	galantide (M 15)IBA 08/2010 - 02/2010
2	Galanin Receptors (Galanin Receptor)IBA 08/2010 - 02/2010
2	GalaninIBA 03/2010 - 02/2010
1	cyclo(Arg-Pro) (CI 4)IBA 05/2016
1	Dihydrotachysterol (AT 10)IBA 09/2014
1	salicylhydroxamic acid (SHAM)IBA 09/2014
1	Alanine Transaminase (SGPT)IBA 07/2012
1	BilirubinIBA 07/2012
1	Octreotide (Sandostatin)FDA LinkGeneric 08/2010
1	Peptides (Polypeptides)IBA 06/2010
1	Lipase (Acid Lipase)FDA Link 03/2010
1	Amylases FDA Link 03/2010
1	Peroxidase (Myeloperoxidase)IBA 03/2010
1	Neurokinin-1 Receptor AntagonistsIBA 02/2010
1	Substance PIBA 02/2010
1	Cholecystokinin (Pancreozymin)IBA 04/2006
1	EnzymesIBA 04/2006
1	CitrullineIBA 01/2005
1	Arginine (L-Arginine)FDA Link 01/2005
1	Carbachol (Carbastat)FDA Link 01/2005
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2005
1	OrnithineIBA 01/2005
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2005
1	TrypsinIBA 10/2003
1	CholesterolIBA 03/2003
1	Endothelins (Endothelin)IBA 09/2002

Therapy/Procedure

4	Therapeutics 05/2016 - 04/2002
3	Bariatric Surgery 01/2019 - 07/2012
3	Nerve Block (Nerve Blocks) 05/2016 - 09/2014
3	Cholecystectomy 04/2006 - 08/2002
2	Glycemic Control 05/2016 - 05/2016
2	Injections 08/2010 - 02/2010
1	Sphincterotomy 10/2020
1	Intraperitoneal Injections 03/2010
1	Pancreaticoduodenectomy 03/2010
1	Prostheses and Implants (Prosthesis) 01/2006
1	Topical Administration 01/2005
1	Intra-Arterial Infusions 01/2005
1	Intravenous Infusions 01/2005
1	Herniorrhaphy 01/2005